Improving non-small-cell lung cancer survival through molecular characterization: Perspective of a multidisciplinary expert panel

Fernandes, M. G. O.; Vilariça, A. S.; Fernandes, B.; Camacho, C.; Saraiva, C.; Estevinho, F.; Bastos, H. Novais e; Lopes, J. M.; Fidalgo, P.; Garrido, P.; Alves, S.; Silva, S.; Sequeira, T.; Barata, F.

http://hdl.handle.net/10400.1/26447

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
Improving non-small-cell lung cancer survival through molecular characterization: Perspective of a multidisciplinary expert panel.pdf		281.56 KB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

Resumo(s)

The management of NSCLC remains challenging, and the integration of data from predictive biomarkers in routine clinical practice can contribute to an optimal, individualized patient approach, particularly given the rapid emergence of effective targeted therapies. When considering molecular biomarker testing, the choice of the biomarker panel, target population, testing approach, and turnaround time are key issues that, when properly addressed, can improve the survival outcomes of NSCLC patients.

Palavras-chave

Of American Pathologists Testing Guideline Acquire resistance Clinical Oncology EGFR mutation Association College Selection NSCLC ALK

URI

http://hdl.handle.net/10400.1/26447

Editora

Informa UK Limited

DOI

10.1016/j.pulmoe.2022.11.009

Coleções

ULS_10.1-MED-Artigos

Licença CC

cclicense-by-nc-nd

Métricas Alternativas

Ver registo completo